Today in celebration of its 25th anniversary, the Foundation for Women’s Cancer with the Society of Gynecologic Oncology released a comprehensive report on the most recent advances in the detection and treatment of gynecologic cancers.
The 2016 State of the … Read more
Tesaro has opened an expanded access program (EAP) in the United States for their investigational poly ADP ribose polymerase (PARP) inhibitor, niraparib.
Now, niraparib is can be available, to treat a patient who meet certain criteria, with a serious disease … Read more
As we step into 2017, a big question looming in the minds of all stakeholders in the cancer research arena is: What is the future of cancer research in the new administration? Members of Congress on both sides of the … Read more
Fewer than half of women diagnosed with ovarian cancer live for five years or more. Sarah Adams, MD, a cancer doctor at the UNM Comprehensive Cancer Center, hopes a new therapy that delivers a one-two punch to cancer cells will … Read more
By: Annette McElhiney
Many of you have already read Dr. Maurie Markman’s article “In Ovarian Cancer Advancements, Finding New Biomarkers is Key” posted in the Clearity blog. It provoked me as an ovarian cancer survivor and non-medical professional … Read more
The search for validated, actionable biomarkers may be more important than initiating more phase 3 trials in the field of ovarian cancer, according to Maurie Markman, M.D.
“In the ovarian cancer arena, we have 30 years of history of doing … Read more
By: Helen Palmquist
In May 1987 when I was 41, I suddenly noticed my abdomen was getting large. I phoned my brother, an obstetrician and gynecologist, long distance to tell him I looked four or five months pregnant. He told … Read more
Testing for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.
Scientists found that defects in a gene called ARID1A caused … Read more
Heavily pre-treated patients with recurrent ovarian cancer have limited options when it comes to regimens that can control disease while maintaining a satisfactory quality of life.
Now, a phase II open-label study has demonstrated that a combination of the camptothecin … Read more
By: Annette McElhiney
Only a night from old to new!
Only a night, and so much wrought!
The Old Year’s heart all weary grew,
But said: The New Year rest has brought.”
The Old Year’s hopes its heart laid down,… Read more
Two thin tubes that connect the ovaries to the uterus have assumed an outsize role in the battle against ovarian cancer. Research increasingly points to the likelihood that some of the most aggressive ovarian cancers originate in the fallopian tubes. … Read more
Three weeks before her wedding day, Cheyann Shaw uploaded a video to YouTube, a space the fitness fanatic regularly filled with workout clips and health tips. But this time was different: She was now using the social video platform for … Read more
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to rucaparib (Rubraca) to treat women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA… Read more
By: Annette McElhiney
As an amateur artist who paints to heal, I see the various stages I’ve been through in my ovarian cancer journey hanging on the walls surrounding me. Some paintings are full of joy as when I first … Read more
A 14-year-old cancer survivor was cast in her dream role this holiday season only a year after the disease had dashed her hopes to perform as Clara in the Christmas classic The Nutcracker. Caitlyn Feddock, who will perform the role … Read more
Delivering bad news to a patient is one of the toughest parts of being a medical professional. As an ob/gyn, whenever I had a patient that showed signs of ovarian, cervical or uterine cancer, it was my responsibility to inform … Read more
Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.
The approval … Read more
Arkansas, California, Florida, Maine, Massachusetts, Nevada, and North Dakota passed some form of marijuana legalization on Election Day 2016, potentially reducing barriers for patients with cancer hoping to use marijuana to relieve symptoms of pain or to increase appetite as … Read more
There has been major progress in treating gynecologic malignancies in recent years, especially for ovarian cancer, says Douglas A. Levine, M.D., a member of The Clearity Foundation’s Scientific Advisory Board.
For example, PARP inhibition has gained impressive traction as a … Read more
Lynparza (olaparib) demonstrated improved progression-free survival (PFS) compared to the placebo arm for patients with ovarian cancer, according to findings from the phase 3 SOLO-2 trial. The single-agent PARP inhibitor was tested in the maintenance setting for patients with advanced … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
